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ABSTRACT 
 
Cyclic nucleotide phosphodiesterase (PDE)3 and PDE4 provide the major PDE activity 
in cardiac myocytes and shape β1-adrenoceptor-dependent cardiac cAMP signaling but 
their role in regulating β2-adrenoceptor-mediated responses is less well known. We 
investigated potential differences in PDE3 and PDE4 activities between right (RV) and 
left (LV) ventricular myocardium, and their role in regulating β2-adrenoceptor effects.  
PDE3 activity in the microsomal fraction was lower in RV than in LV but was the same 
in the cytosolic fraction. However, no significant difference between RV and LV was 
found when the PDE4 activity was studied. β2-adrenoceptor activation increased 
inotropism and lusitropism  in LV when measured in the presence of either the PDE3 
inhibitor cilostamide, the PDE4 inhibitor rolipram or a non-selective PDE inhibitor 
IBMX. However, the joint inhibition of both PDE3 and PDE4 was necessary in RV to 
uncover β2-adrenoceptor-induced inotropic and lusitropic effects. Our results indicate 
different regulation of β2-adrenoceptor-mediated contractility by PDE3 and PDE4 in 
RV and LV of the rat heart. In the case of PDE3 due to a different contribution of the 
enzyme in the microsomal fraction whereas in the case of PDE4 it can be attributed to 
differences in the intracellular distribution and coupling to β2-adrenoceptors.       
    
Keywords:  
PDE3-4 activities 
β2-adrenoceptor activation 
Inotropy 
Lusitropy 
Interventricular difference 
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1. Introduction 
 
The heart can be considered as two independent pumps, one delivering blood to 
the lungs and the other to the rest of the body. Because the contractile work performed 
by each side of the heart is different, the anatomy as well as the mechanical and 
biochemical signaling of right ventricle (RV) and left ventricle (LV), the most important 
functional parts of the heart, are also different (Cadete et al., 2012; Pandit et al., 2011).  
The sympathetic nervous system plays a pivotal role in regulating cardiac 
contractility, mainly through the activation of β-adrenoceptors, of which β1- and β2-
adrenoceptors are the predominant  subtypes expressed in the heart in many mammalian 
species, including human (Woo and Xiao, 2012). The effect of β1-adrenoceptor 
activation on cardiac contractility has been extensively studied and it is known to 
produce a cAMP-dependent contractile effect by activating the stimulatory G 
protein/adenylyl cyclase/cAMP pathway (Brodde et al., 2006).  The inotropic response 
to cardiac muscle β2-adrenoceptor activation is less straightforward and, indeed, it was 
initially thought that this receptor, although present in the myocardium, was not 
involved in the contractile response (Freyss-Beguin et al., 1983; Juberg et al., 1985). 
However, more recent evidence indicates that β2-adrenoceptor can also induce an 
inotropic effect although it is negated by the activity of cyclic nucleotide 
phosphodiesterase (PDE) enzymes, which break down cAMP into 5’-AMP (Perez-
Schindler et al., 2013). Indeed, non-selective PDE inhibition by IBMX unmasks a 
positive inotropic effect of salbutamol mediated by β2-adrenoceptor in the RV of the rat 
heart (Gonzalez-Muñoz et al., 2009). 
PDEs are grouped into different families of which PDE3 and PDE4 account for 
most of the PDE activity in cardiomyocytes (Verde et al., 1999; Rochais et al., 2006). 
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PDE3 exhibits a very low Michaelis constant (Km), with a value of between 0.1 and 0.8 
M for both cAMP and cGMP, and a relatively low maximal velocity (Vmax), which is 
higher for cAMP than for cGMP (Degerman et al., 1997). On the other hand, PDE4 is a 
cAMP-specific PDE with a Km in the range of 1 to 10 M and Vmax values considerably 
lower than those of PDE3 (Bender and Beavo, 2006). PDE activity is not evenly 
distributed throughout the heart (Demirel-Yilmaz et al., 2012) and differences between 
RV and LV have been reported (Shan and Margulies, 2011; Soler et al., 2014). Both, 
PDE3 and PDE4 regulate 1-adrenoceptor mediated contractility in rodent myocardium 
(Juan-Fita et al., 2003; Rochais et al., 2006). However, the interventricular regulation of 
2-adrenoceptor-mediated effects by PDEs is less well known. In the present work we 
have investigated the contribution of PDE3 and PDE4 in rat ventricle and whether or 
not they differentially regulate β2-adrenoceptor-mediated responses. For this purpose, 
we isolated microsomal and cytosolic fractions of RV and LV for the biochemical 
characterization of PDE3 and PDE4 activities at a high exogenous cAMP concentration. 
Moreover, using a myocardiac preparation with endogenous cAMP, we compared the 
influence of either the PDE3 inhibitor cilostamide or the PDE4 inhibitor rolipram on 
contractile effects elicited by β2-adrenoceptor activation.   
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2. Materials and methods 
2.1. Animals 
The study was performed in accordance with the European Union Council 
Directive of 22 September 2010 (2010/63/EU) and reviewed and approved by the 
Ethical Committee of the University of Murcia. Male Sprague-Dawley rats (250-350 g) 
were rendered unconscious instantaneously by cerebral concussion and euthanized by 
rapid exsanguination, after which the chest was opened  and the heart rapidly removed 
and placed in Tyrode solution of the following composition: 136.9 mM NaCl, 5 mM 
KCl, 1.8 mM CaCl2, 1.5 mM MgCl2, 0.4 mM NaH2PO4, 11.9 mM NaHCO3 and 5 mM 
dextrose. 
 
2.2. Cytosolic and microsomal fractions 
Subcellular fractionation of the cardiac tissue was achieved by mechanical 
homogenization and differential sedimentation (Smith et al., 1997; Soler et al., 2014), 
using free wall from right or left rat ventricle muscle as the starting material. The 
cytosolic fraction of LV or RV was the supernatant of the 60 min centrifugation at 
51,000 g and the microsomal fraction of LV or RV was the corresponding pellet once 
resuspended and resedimented at 100,000 g for 40 min. Cytosolic extracts were freed 
from phosphate and nucleotides by gel filtration through chromatographic minicolumns 
(Penefsky, 1977). Isolated fractions were aliquoted and stored at 80 oC for further use.   
 
2.3. Protein quantitation 
The total concentration in the isolated fractions was measured using a kit based 
on the bicinchoninic acid method and bovine serum albumin as standard protein.  
 
6 
 
2.4. PDE activity 
A colorimetric procedure adapted to a microtiter plate was used. Essentially, the 
PDE activity product 5’-AMP was further cleaved under non-rate limiting conditions by 
excess 5’-nucleotidase, and the phosphate (Pi) released was quantified by the malachite 
green method (Lanzetta et al., 1979). cAMP hydrolysis was measured at 37 
o
C in a 100 
l reaction medium containing 10 mM Tris-HCl, pH 7.4, 25 mM NaCl, 0.2 mM MgCl2, 
100 M cAMP, 5’-nucleotidase at 50 U/l and the corresponding aliquot of the 
cytosolic or microsomal extract. The reaction was stopped at different times by 200 l 
malachite green reagent and samples were processed as previously described (Soler et 
al., 2014). The initial rate of cAMP hydrolysis was determined using a plot of 
absorbance at 660 nm vs. time and the standard curve of 5’-AMP vs. Pi. The enzyme 
activity of PDE3 or PDE4 was evaluated by subtracting the PDE activity measured in 
the presence of a selective inhibitor from the activity measured in its absence. In these 
experiments, the cAMP concentration was 100 M. Since the inhibitory effect may be 
dependent on substrate concentration (Yung-Chi and Prusoff, 1973), pilot assays were 
conducted to determine the effective concentration range for each inhibitor (10 M 
cilostamide, 30 M rolipam). In the presence of 100 M cAMP, the inhibition of PDE3 
by 10 M cilostamide and PDE4 by 30 M rolipam was additive and total PDE activity 
was inhibitable by IBMX. Activity data are expressed as nmol Pi/min/mg protein that 
are equivalent to nmol 5’-AMP/min/mg protein, while the contribution of specific PDE 
families are expressed as a percentage with respect to the total PDE activity. 
 
2.5. Western blot of PDE3A 
 The separation and detection of PDE3A were performed by standard procedures. 
Briefly, aliquots of 100 g protein were subjected to 7% sodium-dodecyl-sulfate-
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polyacrylamide minigel electrophoresis in Laemmli buffer and then electroblotted by 
semi-dry transfer. After blocking, the blotted membrane was successively exposed to 
rabbit PDE3A antibody (1:200) and peroxidase-conjugated anti-rabbit IgG (1:5000). 
The protein loading control was performed after stripping by reexposing the blotted 
membrane to rabbit extracellular signal-regulated kinase (ERK) antibody (1:7500) 
followed by incubation with anti-rabbit IgG conjugated to peroxidase (1:5000). 
Immunoreactive bands were detected with the Amersham ECL prime western blotting 
detection reagent from GE Healthcare (Madrid, Spain) and ChemiDoc XRS+ molecular 
imager from Bio-Rad Laboratories (Madrid, Spain). Densitometric quantitation was 
carried out with Gel-Pro Analyzer 3.1 software from Sigma. 
 
2.6. Paced rat ventricular tissues 
 Right ventricular strips (10 mm long, 1 mm wide and 0.5 mm thick) and left 
ventricular papillary muscles were mounted longitudinally between two platinum 
electrodes in Tyrode solution, maintained at 37 ºC, pH 7.4 and gassed with 95% O2 and 
5% CO2. The preparations were electrically stimulated for 1 ms with a Grass SD-9 
stimulator (Quincy, MA, USA) at a frequency of 1 Hz and supramaximal (threshold + 
25%) voltage. A length-force curve was obtained and the tissues were left at the length 
associated with the maximal developed force (Gonzalez-Muñoz et al., 2008). 
Contractions were measured using a Grass FT-03 force-displacement transducer 
(Quincy, MA, USA) and displayed on a computer screen using a Stemtech amplifier 
(Houston, TX, USA) and ACODAS software from Dataq Instruments (Akron, OH, 
USA). Tissues were allowed to equilibrate for 45-60 min before drug challenge.  
 To investigate the β2-adrenoceptor-mediated inotropic effect, concentration-response 
curves for the β2-adrenoceptor agonist salbutamol were obtained in the presence of the 
8 
 
β1-adrenoceptor antagonist CGP-20712A. Salbutamol concentrations were increased 
stepwise by 0.5 log unit, as soon as the response to the previous concentration had 
stabilised. Cumulative concentration-response curves for the β2-adrenoceptor-mediated 
effect of salbutamol, in the presence of 300 nM CGP-20712A, were determined in the 
absence or after 15 min in the presence of the non-selective PDE inhibitor IBMX (30 
μM). Alternatively, selective PDE inhibitors cilostamide (0.1 μM) or rolipram (3 μM) 
which effectively inhibit PDE3 (Verde et al., 1999) or PDE4 (Monguillo et al., 2004) 
activity, respectively were used. Only one concentration-response curve for salbutamol 
+ CGP-20712A in the absence or presence of the above indicated drugs was determined 
in the same ventricular tissue.  
 For comparison, we also investigate the regulation of β1-adrenoceptor-mediated 
contractility by PDE3 or PDE4 in left ventricular papillary muscle since it has already 
been studied in electrically-driven right ventricular strips (Juan-Fita et al., 2003). For 
this purpose, we used noradrenaline and preparations were pretreated with 
desmethylimipramine (2 µM), phentolamine (1 µM) and ICI-118551 (50 nM) to inhibit 
noradrenaline neuronal uptake and α- and β2-adrenoceptors, respectively. In these 
conditions, cumulative concentration-response curves for noradrenaline were obtained 
in the absence or presence of either cilostamide (0.1 µM) or rolipram (3 µM). To 
confirm whether PDE inhibition only affected cAMP-mediated inotropy, concentration-
response curves were obtained for ouabain, as a prototype of non-cAMP-dependent 
inotropic drug, in the absence or presence of the non-selective PDE inhibitor IBMX. 
 Drugs were added to a 30 ml organ bath in a volume smaller than or equal to 0.1 ml. 
Experiments were terminated by raising the Ca
2+
 concentration to 9 mM, which 
produced a maximal inotropic response, and the results are expressed as percentages of 
this effect and also in mN. The relaxation phase of the isometric twitch was also studied 
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by measuring the time-to-half relaxation (t1/2), which is a good index of isometric 
relaxation in mammalian myocardium (Brutsaert and Sys, 1989)  
 
2.7.  Drugs and other products  
Salbutamol, (±)-2-hydroxy-5-(2-((2-hydroxy-3-(4-(1-methyl-4-
(trifluoromethyl)-1H-imidazol-2-l)phenoxy)propyl)amino)ethoxy)-benzamide 
methanesulfonate (CGP-20712A), (±)-1-(2,3-(dihidro-7-methyl-1H-inden-4-yl)oxy)-3-
(1-methylethyl)amino)-2-butanol hydrochloride (ICI-118551), 3-isobutylmethylxantine 
(IBMX), cilostamide, rolipram, noradrenaline and ouabain were obtained from Tocris 
Bioscience (Bristol, UK) whereas desmethylimipramine and phentolamine were from 
Sigma-Aldrich (Madrid, Spain).   
cAMP, 5’-AMP and 5’-nucleotidase from Crotalus atrox venom were products 
from Enzo Life Sciences (Farmingdale, NY, USA). Pierce
®
 BCA protein assay kit was 
from Thermo Fisher Scientific (Rockford, IL, USA) and BioGel P-6DG for gel filtration 
was from Bio-Rad (Hercules, CA, USA). Polyvinylidene difluoride Amersham Hybond 
P 0.45 membrane for electroblotting was from GE Healthcare (Madrid, Spain). Rabbit 
antibodies anti-human PDE3A (sc-20792) and anti-rat ERK (sc-154) were from Santa 
Cruz Biotechnology (Heidelberg, Germany) and secondary antibody anti-rabbit IgG 
conjugated to horseradish peroxidase (W4011) was from Promega Biotech Ibérica 
(Madrid, Spain). All other reagents for the biochemical procedures were analytical 
grade and provided by Sigma-Aldrich (Madrid, Spain).  
 
2.8. Statistics 
Enzyme activity data are mean values of a number of determinations (n)  
S.E.M. Observed differences were analyzed by the Student t-test using SigmaPlot 11.0 
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from Systat software (San Jose, CA, USA). Functional results are also expressed as 
mean ± S.E.M. Student’s t test or one-way analysis of variance followed by the Fisher 
LSD post-hoc test were used for multiple comparisons. Values of P  0.05 were 
considered to be statistically significant. 
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3. Results 
 
3.1. PDE3 and PDE4 in subcellular fractions 
 
The in vitro enzyme activity was measured in the presence of selective inhibitors 
to evaluate the contribution of specific PDE families. Experiments performed at 
saturating conditions of substrate both in the absence or presence of 10 M cilostamide 
revealed that the contribution of microsomal PDE3 to total PDE activity was lower in 
RV (28.5  4.2%) than in LV (40.3  1.1%) (n = 4, P  0.05) (Fig. 1A). That is, PDE3 
activity in the microsomal fraction was around 29% lower in RV than in LV. When the 
cytosolic fraction was analyzed, PDE3 activity was 43.0  2.9% in RV and 48.9  5.1% 
in LV (n = 4, P > 0.05). In this case, the difference was not statistically significant.    
 A similar set of experiments performed in the absence or presence of 30 M 
rolipram indicated that the contribution of PDE4 to the total activity was relatively low 
in both microsomal and cytosolic fractions, displaying values of 9.4  1.6% in 
microsomes of RV (n = 4), 10.6  5.0% in microsomes of LV (n = 4), 26.5  2.5% in 
cytosol of RV (n = 4) and 26.8  4.5% in cytosol of LV (n = 4) (Fig. 1B). The 
difference between microsomes of RV and LV or cytosol of RV and LV did not reach 
the significance level.  
PDE3A and PDE3B subfamilies are products of homologous genes that exhibit 
different patterns of expression. Since PDE3A is more abundantly expressed in murine 
heart than PDE3B (Chung et al., 2015), the observed differences in PDE3 activity were 
also analyzed by Western blot. As can be seen (Fig. 1C), the relative expression of 
PDE3A was higher in LV than in RV and the difference was more evident in the 
microsomal than in the cytosolic fraction.   
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3.2. Salbutamol + IBMX 
To ascertain whether inhibition of PDE activity unmasks β2-adrenoceptor-
mediated inotropic and lusitropic effects in LV, as it did in RV (Gonzalez-Muñoz et al., 
2009), we tested the effect of salbutamol + CGP-20712A, in the absence or presence of 
the non-selective PDE inhibitor IBMX, in left ventricular papillary muscle. Salbutamol 
alone at 0.1 to 10 μM had no inotropic effect in LV but produced a concentration-
dependent contractile effect in the presence of 30 μM IBMX. This effect was prevented 
by the β2-adrenoceptor antagonist ICI-118551 (50 nM), indicating that it was dependent 
on β2-adrenoceptor activation (Fig. 2). As expected, IBMX (30 μM) failed to increase 
the contractile effect of the non-cAMP-dependent inotropic agent ouabain both in right 
and left ventricular myocardium. Indeed, neither the –log EC50 (5.5 + 0.9, n = 4 in the 
absence and 6.0 + 0.7, n = 4 in the presence of IBMX, P > 0.05), nor the Emax (48.3 + 
6.4, n = 4 in the absence and 40.6 + 2.7, n = 4 in the presence of IBMX, P > 0.05) of 
ouabain were modified by IBMX in RV. Similarly, IBMX in LV did not alter the –log 
EC50 (5.8 + 0.4, n = 4 in the absence and 5.5 + 0.6, n = 4 in the presence of IBMX, P > 
0.05) or the Emax (30.3 + 5.2, n = 4 in the absence and 37.5 + 4.2, n = 4 in the presence 
of IBMX, P > 0.05) of ouabain. Moreover, IBMX had no inotropic effect in the 
presence of the β1-adrenoceptor antagonist CGP-20712A (when investigating the 
interaction IBMX-β2-adrenoceptor activation). However, in the absence of CGP-
20712A (when studying the IBMX-ouabain interaction), IBMX increased inotropy by 
46.8 + 7.3% (n = 4) in RV and 37.8 + 6.7% (n = 4) in LV, compared to basal 
contractility. This indicates that PDE inhibition enhances inotropic effect of basal 
cAMP levels, mainly generated by endogenous catecholamines through β1-adrenoceptor 
activation.  
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Salbutamol at 3 M had no lusitropic effect in LV when added after 
preincubation with CGP-20712A, the t1/2 relaxation time being 48.5 + 1.9 ms (n = 5) in 
the absence and 47.2 + 1.5 ms (n = 5, P > 0.05) in the presence of salbutamol + CGP-
20712A. However, the application of 3 μM salbutamol when papillary muscles were 
preincubated with CGP-20712A and IBMX, which produced a maximal inotropic effect 
(see Fig. 2), produced a lusitropic effect that was again prevented by preincubation with 
50 nM ICI-118551 (Fig. 3).  
 
3.3. Contractile effects regulation by PDE3 and PDE4  
Selective inhibition of PDE3 by cilostamide (0.1 μM) or PDE4 by rolipram (3 
μM) in cardiac muscle preparations failed to produce an inotropic effect by themselves 
or to promote β2-adrenoceptor- mediated contractile effect induced by salbutamol in 
RV. Nevertheless, the joint inhibition of PDE3 and PDE4 by cilostamide + rolipram 
unmasked a concentration–dependent positive inotropic effect of salbutamol + CGP-
20712A in this tissue (Fig. 4). However, the single inhibition of either PDE3 or PDE4 in 
LV, when samples were already preincubated with CGP-20712A was devoid of 
contractile effect but had a positive inotropic effect when salbutamol was added. This 
inotropic effect was further increased when both PDE3 and PDE4 were simultaneously 
inhibited (Fig. 5).  
For comparison, we studied the effect of PDE3 and PDE4 inhibition on β1-
adrenoceptor-mediated inotropy in LV following its previous evaluation in RV by our 
group (Juan-Fita et al., 2003). For this purpose, we tested the effect of noradrenaline in 
the absence or presence of either 0.1 µM cilostamide or 3 μM rolipram. Each inhibitor 
produced a leftward shift of the concentration-response curve for noradrenaline (Fig. 6) 
and significantly changed the –log EC50 value from 6.75 + 0.06 (n = 4) when added 
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alone to 7.1 + 0.10 in the presence of 0.1 µM cilostamide (n = 4, P < 0.05) or 7.2 + 0.15 
in the presence of 3 µM rolipram (n = 4, P < 0.05).  
Whether cilostamide and rolipram affected the β2-adrenoceptor-mediated 
lusitropic effect of salbutamol in ventricular myocardium was also studied. Neither 
cilostamide nor rolipram on their own affected the t1/2 relaxation time in RV and only 
the joint inhibition of PDE3 plus PDE4 reduced this time in this tissue (Fig 7A). 
However, salbutamol + CGP-20712A reduced the t1/2 relaxation time after the single 
inhibition of either PDE3 or PDE4 in LV, and the joint inhibition of PDE3 and PDE4 
further increased the lusitropic effect of salbutamol + CGP-20712A (Fig. 7B).   
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4. Discussion  
PDE3 and PDE4 are crucial in regulating cAMP-mediated effects (Verde et al., 
1999; Rochais et al., 2006) since they account for the largest part of cAMP degradation 
under physiological conditions in myocardium. However, whether the catalytic activity 
and contribution of PDE3 and PDE4 differs in RV and LV is unknown and has been 
evaluated in the present study.  
Current data on the contribution of PDE families in heart muscle are difficult to 
compare due to different experimental conditions used for evaluation, namely sample 
preparation and concentration of substrate (Rochais et al., 2006; Richter et al., 2011; 
Johnson et al., 2012). It is known that cAMP is compartmentalized and subjected to 
time-dependent changes, however if we assume the average basal value of 1.2 M 
(Iancu et al., 2008), PDE3 activity is working at 73% saturation whereas PDE4 only 
reaches 18%. Under non-saturating conditions, the contribution of PDE families is 
dependent on cAMP concentration. Our biochemical assays were performed in the 
presence of saturating substrate concentration in order to evaluate the activity of all the 
PDE families, including the high Km (low affinity) PDE2 (Soler et al., 2014). In this 
way, the contribution of specific PDEs is independent of cAMP concentration. In fact, 
the contribution of PDE3 or PDE4 to the total activity is dependent on kinetic constants, 
cAMP concentration and protein content. This means that for any cAMP concentration, 
differences in activity between RV and LV are only dependent on protein content. It 
should be noted that our aim was to identify potential differences in PDEs regulation. In 
this respect, we analyzed the contribution of PDE3 and PDE4 in microsomal and 
cytosolic fractions. The microsomal fraction is the most directly associated with cardiac 
contractility regulation owing to the presence of sarcoplasmic reticulum membrane that 
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is known to contain PDE3A as component of a multiprotein signaling complex (Beca et 
al., 2013) and members of the PDE4 family (Houslay et al., 2007).  
The functional results of the present work show that, as in RV (Gonzalez-Muñoz 
et al., 2009), PDE activity also blunts the inotropic and lusitropic effects elicited by β2-
adrenoceptor in the LV of rat heart. However, β2-adrenoceptor-mediated inotropic and 
lusitropic responses are differentially regulated by PDE3 and PDE4 in right and left 
ventricular myocardium. Indeed, the sole inhibition of either PDE3 or PDE4 unmasks 
β2-adrenoceptor-mediated inotropic and lusitropic effects in LV but not in RV. In the 
latter case, the combined inhibition of both isoenzymes was necessary to produce such 
effects. The single inhibition of either PDE3 by cilostamide, or PDE4 by rolipram had 
no effect on basal contractility in our preparation, which is consistent with the notion 
that in rat myocardium neither a selective inhibitor of PDE3 nor of PDE4 increases 
force of contraction when given alone, but they do increase contractility when 
administered in combination. Thus, inhibition of a sufficient proportion of PDEs to rise 
cAMP generated mainly through β1-adrenoceptor activated by endogenous 
catecholamines is necessary (see Nicholson et al., 1991 for review). This agrees with 
our results in which the joint inhibition of PDE3 and PDE4 by IBMX increased 
ventricular contractility when the β1-adrenoceptor was not inhibited by CGP-20712A 
(when assessing ouabain-IBMX interactions). However, in the presence of the β1-
adrenoceptor antagonist CGP-20712A, the combined inhibition of PDE3 and PDE4 by 
IBMX or rolipram+cilostamide failed to enhance contractility.   
Activation of β-adrenoceptors by catecholamines plays a pivotal role in 
regulating cardiac contractility, and β1- and β2-adrenoceptors are predominantly 
expressed in the heart of various species, including human (Brodde et al., 2006). PDEs 
play an essential role in tailoring β-adrenoceptors responses  (Bender and Beavo, 2006) 
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but their activities do not seem to be evenly distributed throughout the myocardium 
(Shan and Margulies, 2011; Demirel-Yilmaz et al., 2012; Soler et al., 2014). Acute 
stimulation of β1-adrenoceptors produces an inotropic effect, which is regulated by 
PDE3 and PDE4 in both right (Juan-Fita et al 2003) and left (present work) ventricular 
myocardium of rat heart. However, the mechanism(s) underlying the inotropic effect of 
β2-adrenoceptor activation is less straightforward. Indeed, β2-adrenoceptor agonists 
failed to enhance cardiac contractility in rodent, unlike β1-adrenoceptor agonists 
(Freyss-Beguin et al., 1983; Juberg et al., 1985). This seems to be due to lower cAMP 
production resulting from β2-adrenoceptor activation, compared to β1-adrenoceptor 
activation, as has been demonstrated in rat ventricular myocardium (Juan-Fita et al., 
2003; Gonzalez-Muñoz et al., 2009) as well as in isolated rat ventricular myocytes 
(Rochais et al., 2006). In addition, the lower cAMP that is produced seems to be avidly 
hydrolysed by PDEs (Perez-Schindler et al., 2013) and so the overall inhibition of PDEs 
unmasked β2-adrenoceptor-mediated inotropic and lusitropic effects in the RV of rat 
myocardium (Gonzalez-Muñoz et al., 2009). Our results show that IBMX promoted β2-
adrenoceptor-mediated inotropic effect and lusitropic effects in left ventricular papillary 
muscle thus indicating that β2-adrenoceptor-mediated contractile effects are negated by 
PDE activity in both RV (Gonzalez-Muñoz et al., 2009) and LV (present results).To 
explore β2-adrenoceptor-mediated effects we have used salbutamol which is an effective 
β2-adrenoceptor agonist widely used in clinic for treating asthma, particularly during 
acute exacerbations (Bel, 2013; Neame et al., 2015). Our results also indicate that the 
single inhibition of PDE3 or PDE4 in LV unmasks β2-adrenoceptor-mediated inotropic 
and lusitropic responses and this effect is further enhanced by the combined inhibition 
of both PDE families. This agrees with previous results in adult rat ventricular myocytes 
showing that the inhibition of either of these two PDE families enhances the effect of 
18 
 
β2-adrenoceptors on the L-type Ca
2+
 current, which plays a determinant role in 
triggering myocardial contractility (Rochais et al., 2006). However, the joint inhibition 
of both PDE3 and PDE4 by IBMX (Gonzalez-Muñoz et al., 2009) or cilostamide + 
rolipram (present results) was necessary to uncover β2-adrenoceptor-induced inotropic 
and lusitropic effects in RV. These results indicate that both PDEs are necessary to 
circumvent the inotropy elicited by β2-adrenoceptor in RV, whereas either PDE3 or 
PDE4 individually is sufficient to prevent β2-adrenoceptor-induced contractility in LV. 
Disparities in β2-adrenoceptor density do not seem to be responsible for this difference 
since β2-adrenoceptors expression is virtually the same in both RV and LV of the rat 
heart (Horinouchi et al., 2006; Myslivecek et al., 2006). The lower contribution of 
microsomal PDE3 activity in RV with respect to LV, accompanied by lower protein 
expression, could be expected to provide smaller cAMP signals when inhibited. 
However, interventricular differences in PDE4 activity cannot explain the differential 
regulation of β2-adrenoceptor-mediated contractile effects in RV and LV. In this case, it 
can be attributed to the different intracellular distribution and coupling to β2-
adrenoceptors in right and left ventricular myocardium (Bethke et al., 1993; Smith et al., 
1993; Molina et al., 2014).  
RV and LV differ in structure and function and they work under very different 
mechanical conditions. RV ejects blood at low pressure to the lungs in an almost 
continuous manner, in contrast to the relatively high pressure pulsatile flow generated 
by LV. Thus, the existence of anatomical, functional and biochemical differences 
between right and left ventricle, such as wall thickness, maximal sarcomere shortening, 
Ca
2+
 dynamics, α-myosin heavy chain isoenzymes expression and ionic currents density 
(Brunet et al., 2004; Walker and Buttrick, 2009) is not surprising. Some evidence also 
points to differential contribution of PDEs in right and left ventricular myocardium. 
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Indeed, there are reports of higher PDE5 activity in right than in left ventricle of feline 
heart (Shan and Margulies, 2011) and also variations of PDE activities in different 
regions of the rodent heart (Demirel-Yilmaz et al., 2012; Hua et al., 2012; Soler et al., 
2014). The results of the present work showing that PDE3 and PDE4 differently 
regulate β2-adrenoceptor-mediated inotropic and lusitropic effects in right and left 
ventricular myocardium further support this view. This could be of interest, particularly 
in the setting of the right and left ventricular failure which may require drugs with 
selective ventricular inotropic effect in order to avoid interference with the function of 
the counterpart ventricle (Haddad et al., 2010). However, the clinical relevance of this 
finding remains to be determined.   
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Figure Legends 
 
Fig. 1. PDE activity and protein expression in subcellular fractions of rat ventricle. (A) 
The contribution of PDE3 activity was evaluated in microsomal and cytosolic fractions 
isolated from RV (white bars) or LV (grey bars) and deduced by subtraction from the 
corresponding total activity (n = 4). Significant differences are shown (*). (B) 
Contribution of PDE4 activity in microsomal and cytosolic fractions from RV (white 
bars) or LV (grey bars) were deduced by subtraction from the corresponding total 
activity (n = 4). Differences between groups were not significant. (C) Blot images of 
PDE3A and ERK in microsomes and cytosol from RV and LV. Protein levels of 
PDE3A in RV (white bars) and LV (grey bars) were normalized against the 
corresponding content of ERK2 and expressed on a relative scale. Weak detection of 
ERK1 was observed.  
 
Fig. 2. β2-adrenoceptor- mediated effect of salbutamol on the contraction basal force of 
left ventricular myocardium. In all cases, β1-adrenoceptors were blocked by 300 nM 
CGP-20712A. Representative traces in three electrically-driven  papillary muscles 
showing that salbutamol is devoid of any contractile effect (A) but preincubation with 
the non-selective PDE inhibitor IBMX (30 μM) unmasked a concentration-dependent 
positive inotropic effect of salbutamol (B). The effect was eliminated when the β2-
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adrenoceptor antagonist ICI-118551 (50 nM) was added in preincubation (C).  (D) 
Cumulative concentration-response curves for the effect of salbutamol (●), salbutamol 
in the presence of IBMX (■) or salbutamol in the presence of IBMX + ICI-118551 
(▲). Inotropic responses are expressed as percentage of the effect caused by 9 mM 
Ca
2+
. Each point represents the mean value + S.E.M. (vertical bars) of 5 experiments. 
 
Fig. 3. β2-adrenoceptor-mediated lusitropic effect of salbutamol on left ventricular 
myocardium. Papillary muscles of rat heart were preincubated with 300 nM of the β1-
adrenoceptors  blocker CGP-20712A and 30 μM of the non-selective PDE inhibitor 
IBMX (Control, C). In these conditions, tissues were exposed to 3 μM salbutamol 
(SAL).  (A) original recordings. (B) t1/2 relaxation times. The lusitropic effect of 
salbutamol in the presence of CGP-20712A plus IBMX was prevented by the β2-
adrenoceptor antagonist ICI 118551 (50 nM). Data are expressed as means + S.E.M. of 
5 experiments. * P < 0.05. 
 
Fig. 4. Effect of PDE3 and PDE4 on β2-adrenoceptor-mediated inotropic effect in RV. 
Representative traces showing the effect of 3 μM rolipram (A), 0.1 μM cilostamide (B), 
or the combination of both (C) on salbutamol-evoked contractile response in 
electrically-driven strips of right ventricular myocardium. β1-adrenoceptors were 
blocked by 300 nM CGP-20712A. (D) Cumulative concentration-response curves for 
salbutamol in the presence of the indicated concentrations of either rolipram  (○), 
cilostamide (●) or rolipram + cilostamide (▼). Further details as in the legend of figure 
2. Values are the means + S.E.M. of 4-5 experiments. 
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Fig. 5. Effect of PDE3 and PDE4 on β2-adrenoceptor-mediated inotropic effect in LV. 
Representative traces showing the effect of 3 μM rolipram (A), 0.1 μM cilostamide (B) 
or the combination of both (C) on salbutamol-induced  contractile response in 
electrically-driven papillary muscles. β1-adrenoceptors were blocked by 300 nM CGP-
20712A. (D) Cumulative concentration-response curves for β2-adrenoceptor-mediated 
inotropic effect of salbutamol when measured in the presence of the indicated 
concentrations of either cilostamide (●), rolipram (○) or the combination of both (▼). 
Further details as in the legend of figure 2. Each point represents the mean value + 
S.E.M. of 4-5 experiments. 
 
Fig 6. Effect of PDE3 or PDE4 on β1-adrenoceptor- mediated inotropy in LV. 
Cumulative concentration-response curves in electrically-driven ventricular papillary 
muscle for noradrenaline alone (●) and in the presence of either  0.1 μM cilostamide 
(▼) or 3 μM rolipram (○). Preparations were pretreated with desmethylimipramine (2 
μM), phentolamine (1 μM) and ICI-118551 (50 nM) to inhibit noradrenaline uptake and 
α- and β2-adrenoceptors, respectively. Further details as in the legend to figure 2. Values 
are means + S.E.M. of 4 experiments. 
 
Fig 7.  Effect of PDE3 and PDE4 on β2-adrenoceptor-mediated lusitropic response (t1/2 
relaxation time) in rat ventricular myocardium. Preparations were preincubated with 
300 μM of β1-adrenoceptor blocker CGP-20712A. In these conditions, electrically-
driven right ventricular strips (A) or left ventricular papillary muscle (B) were exposed 
to 3 μM salbutamol (SAL) in the absence (C) or presence of either 0.1 μM cilostamide 
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(CIL), 3 μM rolipram (ROL) or both (CIL + ROL). Values are means + S.E.M. of 4-5 
experiments.  
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